AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Feb 26, 2014

AbbVie to Present at Barclays Global Healthcare Conference 2014

NORTH CHICAGO, Ill., Feb. 26, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference 2014 on Thursday, March 13, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 7:30 a.m. Central time.

Feb 20, 2014

AbbVie Increases Quarterly Dividend

NORTH CHICAGO, Ill., Feb. 20, 2014 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) increased the company's quarterly cash dividend by 5 percent from $0.40 per share to $0.42 per share. 

Feb 20, 2014

AbbVie Announces New Art Gallery Designed To Provide Perspectives On The Impact Of Chronic Inflammatory Diseases

NORTH CHICAGO, Ill., Feb. 20, 2014 /PRNewswire/ -- AbbVie today announced the launch of 'Perspectives – Art, Inflammation and Me', an initiative designed to add a different dimension to the current understanding of immune-mediated inflammatory diseases (IMIDs) and their impact on patients and society.  More than 100 unique artistic expressions from the initiative are being debuted at the 9th Congress of the European Crohn's and Colitis Organisation (ECCO) in Copenhagen, Denmark from February 20th to 22nd.

Feb 19, 2014

AbbVie to Present at Cowen 34th Annual Health Care Conference

NORTH CHICAGO, Ill., Feb. 19, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Cowen and Company 34th Annual Health Care Conference on Wednesday, March 5, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 7:40 a.m. Central time.

Feb 05, 2014

AbbVie Expands Manufacturing Presence with US$320 Million Investment in Singapore

NORTH CHICAGO, Ill., Feb. 5, 2014 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) announces a US$320 million [approximately S$400 million] investment to establish operations in Singapore for small molecule and biologics active drug substance manufacturing. The completed facility will provide manufacturing capacity for emerging compounds within AbbVie's oncology and immunology pipeline to serve markets globally.

Jan 31, 2014

AbbVie Completes Largest Phase III Program of an All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1

NORTH CHICAGO, Ill., Jan. 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the completion of its phase III clinical program and released results of four additional studies designed to assess AbbVie's investigational all-oral, interferon-free therapy with and without ribavirin (RBV) in patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. These results described below confirm previously reported AbbVie data and further demonstrate high sustained virologic response rates 12 weeks post treatment (SVR12) and tolerability in these GT1 patients.

Jan 31, 2014

AbbVie Reports Fourth-Quarter and Full-Year 2013 Financial Results

NORTH CHICAGO, Ill., Jan. 31, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.

Jan 15, 2014

AbbVie Announces Initiation of Pivotal Phase 3 Study of Veliparib (ABT-888) for Patients with Early-Stage Triple-Negative Breast Cancer

NORTH CHICAGO, Ill., Jan. 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a Phase 3 clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888) when added to carboplatin, a chemotherapy, in women with early-stage, triple-negative breast cancer.  The three-arm trial will compare the addition of veliparib plus carboplatin or placebo plus carboplatin to standard neoadjuvant chemotherapy. 

Jan 13, 2014

AbbVie to Host Fourth-Quarter and Full-Year 2013 Earnings Conference Call

NORTH CHICAGO, Ill., Jan. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2013 financial results on Friday, Jan. 31, 2014, before the market opens.

Dec 20, 2013

AbbVie to Present at 32nd Annual J.P. Morgan Healthcare Conference

NORTH CHICAGO, Ill., Dec. 20, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2014. Bill Chase, executive vice president and chief financial officer, will make a formal presentation on the company at 11 a.m. Central time.